Department of Environmental and Forest Biology, SUNY College of Environmental Science and Forestry, Syracuse, New York, USA.
PLoS One. 2011;6(12):e29030. doi: 10.1371/journal.pone.0029030. Epub 2011 Dec 22.
Infectious disease has recently joined poaching and habitat loss as a major threat to African apes. Both "naturally" occurring pathogens, such as Ebola and Simian Immunodeficiency Virus (SIV), and respiratory pathogens transmitted from humans, have been confirmed as important sources of mortality in wild gorillas and chimpanzees. While awareness of the threat has increased, interventions such as vaccination and treatment remain controversial. Here we explore both the risk of disease to African apes, and the status of potential responses. Through synthesis of published data, we summarize prior disease impact on African apes. We then use a simple demographic model to illustrate the resilience of a well-known gorilla population to disease, modeled on prior documented outbreaks. We found that the predicted recovery time for this specific gorilla population from a single outbreak ranged from 5 years for a low mortality (4%) respiratory outbreak, to 131 years for an Ebola outbreak that killed 96% of the population. This shows that mortality rates comparable to those recently reported for disease outbreaks in wild populations are not sustainable. This is particularly troubling given the rising pathogen risk created by increasing habituation of wild apes for tourism, and the growth of human populations surrounding protected areas. We assess potential future disease spillover risk in terms of vaccination rates amongst humans that may come into contact with wild apes, and the availability of vaccines against potentially threatening diseases. We discuss and evaluate non-interventionist responses such as limiting tourist access to apes, community health programs, and safety, logistic, and cost issues that constrain the potential of vaccination.
传染病最近已成为非洲猿类的主要威胁之一,与偷猎和栖息地丧失并列。自然发生的病原体,如埃博拉病毒和猴免疫缺陷病毒(SIV),以及从人类传播的呼吸道病原体,已被确认为野生大猩猩和黑猩猩死亡的重要来源。虽然人们对这一威胁的认识有所提高,但疫苗接种和治疗等干预措施仍存在争议。在这里,我们探讨了疾病对非洲猿类的风险,以及潜在应对措施的现状。通过综合已发表的数据,我们总结了以前疾病对非洲猿类的影响。然后,我们使用一个简单的人口模型来说明一个著名的大猩猩种群对疾病的恢复能力,该模型基于以前记录的疫情。我们发现,从单一疫情中恢复的特定大猩猩种群的预测时间从低死亡率(4%)呼吸道疫情的 5 年,到导致 96%人口死亡的埃博拉疫情的 131 年不等。这表明,死亡率与最近报道的野生种群疾病爆发相当,是不可持续的。考虑到由于野生猿类对旅游的适应程度不断提高,以及保护区周围人口的增长,病原体风险也在不断上升,这一点尤其令人担忧。我们根据人类可能接触野生猿类的疫苗接种率,以及针对潜在威胁疾病的疫苗的可获得性,评估未来疾病溢出的风险。我们讨论并评估了非干预性应对措施,如限制游客与猿类接触、社区卫生计划以及疫苗接种的安全、后勤和成本问题,这些问题限制了疫苗接种的潜力。